Printer Friendly

FDA approves Rebif. (News).

This March, the U.S. Food and Drug Administration (FDA) approved Rebif, a form of interferon beta-1a manufactured by Serono, for treatment of relapsing forms of MS. With the addition of Rebif, there are now five drugs--Avonex, Betaseron, Copaxone, Novantrone, and Rebif--approved in the United States for modifying the course of major forms of MS. Avonex, Betaseron, Copaxone, and Rebif are approved for relapsing forms of MS; Novantrone is approved for progressive as well as rapidly worsening relapsing forms of MS.

The FDA approval was based on results from two clinical trials: the PRISMS study and the EVIDENCE study. (See story on page 45.) Since the results from the PRISMS trial were first announced in 1997, Rebif has been prescribed for MS in over 60 countries worldwide. Rebif is taken by subcutaneous (under the skin) injection three times a week.

Avonex, which is also interferon beta-la, was given a seven-year exclusive U.S. market under the provisions of the Orphan Drug Act. This law provides incentives for pharmaceutical companies to research and develop medications for conditions that affect a limited number of people. Rebif was initially not to be available in the United States until mid-2003, unless clinical superiority of Rebif over Avonex could be demonstrated.

To gain earlier approval in the U.S., Serono sponsored a direct "head-to-head" comparison of Rebif and Avonex in the EVIDENCE trial. In approving Rebif prior to mid-2003, the FDA signaled its view that Rebif showed superiority over Avonex within the confines of the EVIDENCE trial.

Side effects for both Rebif and Avonex--including flu-like symptoms--were in line with what had been reported previously for interferon betas. According to Serano, the approximate price of Rebif is $13,875 annually.

Each of the approved treatments has pros and cons. The choice of therapy for any particular individual should be made in consultation with his or her personal physician.
COPYRIGHT 2002 National Multiple Sclerosis Society
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Inside MS
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 22, 2002
Words:312
Previous Article:Getting disease-modifying drugs in the U.K.
Next Article:Cleveland clinic zeroes in on factors that block natural myelin repair. (News).
Topics:


Related Articles
New interferon drug shows positive results.
FDA decision on Rebif.
Rebif trial disappointing for secondary-progressive MS.
Rebif and Avonex go head-to-head.
Serono seeks FDA approval for Rebif. (News).
FDA approves room-temperature Betaseron. (News).
Rebif [in context].
"Expensive". (The Last Word).
It's official: Medicare covers Avonex. (news).
Consensus Statement revised. (National MS Society).

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters